JANX logo

JANXJanux Therapeutics Inc

$14.19
$0.63
(4.37%)
Today
Closed $13.78
$0.41
(2.98%)
After Hours
Updated: 07:22 PM EDT
Reported EarningsMay 7
Mkt Cap$878.78M
Vol704,482.00
News
all
press releases
Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know
The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 155.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
News Placeholder
More News
News Placeholder
Here's Why You Should Add JANX Stock to Your Portfolio Now
Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates, new studies and expanded partnerships with BMY and MRK.
Zacks
News Placeholder
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates
Janux Therapeutics (JANX) delivered earnings and revenue surprises of +21.83% and -75.11%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter...
Business Wire
News Placeholder
How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%
The consensus price target hints at an 180.4% upside potential for Janux Therapeutics (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
News Placeholder
Janux Therapeutics (NASDAQ:JANX) Upgraded by Truist Financial to Strong-Buy Rating
Truist Financial upgraded Janux Therapeutics to a "strong-buy" rating in a research report on Monday...
MarketBeat
News Placeholder
JonesTrading Has Lowered Expectations for Janux Therapeutics (NASDAQ:JANX) Stock Price
JonesTrading cut their price target on shares of Janux Therapeutics from $50.00 to $28.00 and set a "buy" rating on the stock in a report on Tuesday...
MarketBeat
News Placeholder
JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline
The company said that it came to the decision after completing early-stage trials across multiple solid tumor indications and an internal review of the data.
Stocktwits
News Placeholder
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it will discontinue further...
Business Wire
News Placeholder
Will Acute Care Strength Help Universal Health Offset Q1 Rising Costs?
UHS heads into Q1 earnings with acute care and behavioral health growth, but rising labor and supply costs could cloud the outlook.
Zacks
<
1
2
...
>